{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:53:48Z","timestamp":1791474828173,"version":"4.3.4"},"reference-count":40,"publisher":"American Society for Microbiology","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPPGH5342"],"award-info":[{"award-number":["OPPGH5342"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Albendazole (ALB), a benzimidazole antiparasitic, is widely used in mass drug administration (MDA) campaigns against lymphatic filariasis (LF). It is rapidly metabolized to its active form, albendazole sulfoxide (ALB-OX), which exhibits considerable interindividual variability (IIV) in pharmacokinetics (PK). This variation may affect ALB efficacy in MDA programs. We developed a population pharmacokinetic (PopPK) model characterizing ALB and ALB-OX exposure and identifying demographic and clinical covariates contributing to IIV in patients with LF and healthy individuals. Plasma concentration-time data were pooled from three clinical studies involving ALB co-administered with ivermectin and diethylcarbamazine. Nonlinear mixed-effects modeling was conducted using Phoenix NLME. Covariate effects (e.g., sex, age, infection status) were assessed, and model validation employed visual predictive checks and bootstrapping. Simulations explored covariate impact on exposure. A joint two-compartment model with transit absorption for ALB and pre-systemic ALB-OX formation best described the data. Sex significantly influenced ALB-OX clearance and volume of distribution, with males exhibiting higher clearance and lower exposure. Body weight, age, and LF infection status did not significantly affect PK parameters. Simulations confirmed 33% lower ALB-OX levels in males compared to females following a 400 mg oral ALB dose. This is the first PopPK model of ALB and ALB-OX in LF-endemic populations. It highlights sex as a key covariate explaining IIV in ALB-OX exposure, with implications for optimized dosing in MDA programs. Further studies incorporating pharmacogenetics and pediatric data are warranted.<\/jats:p>\n                    <jats:p>\n                      This study is registered with ClinicalTrials.gov as\n                      <jats:related-object xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" document-id=\"NCT04410406\" document-id-type=\"clinical-trial-number\" source-id=\"10.18810\/clinical-trials-gov\" source-id-type=\"crossref-doi\" source-type=\"clinical-trials-registry\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04410406\">NCT04410406<\/jats:related-object>\n                      ,\n                      <jats:related-object xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" document-id=\"NCT02845713\" document-id-type=\"clinical-trial-number\" source-id=\"10.18810\/clinical-trials-gov\" source-id-type=\"crossref-doi\" source-type=\"clinical-trials-registry\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT02845713\">NCT02845713<\/jats:related-object>\n                      , and\n                      <jats:related-object xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" document-id=\"NCT03664063\" document-id-type=\"clinical-trial-number\" source-id=\"10.18810\/clinical-trials-gov\" source-id-type=\"crossref-doi\" source-type=\"clinical-trials-registry\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03664063\">NCT03664063<\/jats:related-object>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1128\/aac.00562-26","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:13:30Z","timestamp":1791472410000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":0,"title":["Population pharmacokinetics modeling of albendazole and its active metabolite, albendazole sulfoxide in mass drug administration against lymphatic filariasis"],"prefix":"10.1128","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4551-828X","authenticated-orcid":true,"given":"Abdullah","family":"Alshehri","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/052kwzs30","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Clinical Pharmacy, College of Pharmacy, King Khalid University","place":["Abha, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L.","family":"King","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/051fd9666","id-type":"ROR","asserted-by":"publisher"}],"name":"Center for Global Health and Diseases, Department of Pathology, Case Western Reserve University","place":["Cleveland, USA"]},{"id":[{"id":"https:\/\/ror.org\/01vrybr67","id-type":"ROR","asserted-by":"publisher"}],"name":"Veterans Affairs Research Service, VA Medical Center","place":["Cleveland, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4169-5027","authenticated-orcid":true,"given":"Daryl J.","family":"Murry","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00thqtb16","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Pharmacy Practice and Science, University of Nebraska Medical Center","place":["Omaha, USA"]},{"id":[{"id":"https:\/\/ror.org\/00thqtb16","id-type":"ROR","asserted-by":"publisher"}],"name":"Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center","place":["Omaha, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-4017(93)90052-o"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.3347\/kjp.2021.59.3.189"},{"key":"e_1_3_2_4_2","unstructured":"World Health Organization. 2020. Ending the neglect to attain the sustainable development goals: a road map for neglected tropical diseases 2021\u20132030. World Health Organization"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02489-18"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005945"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.355"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00432-21"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1992.tb03783.x"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00278590"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0007325"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1202"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ882"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0011567"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0010497"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4419-9485-1_7"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1D374"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2017.12.037"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.4155\/bio-2018-0110"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1208\/ps030429"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.131"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4419-9485-1"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.5414\/CPP47679"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac020"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.3109\/00498259509061863"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-9556(24)15313-5"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11030134"},{"key":"e_1_3_2_28_2","first-page":"95","article-title":"Nanosizing of drugs: effect on dissolution rate","volume":"10","author":"Dizaj SM","year":"2015","unstructured":"Dizaj SM, Vazifehasl Z, Salatin S, Adibkia K, Javadzadeh Y. 2015. Nanosizing of drugs: effect on dissolution rate. Res Pharm Sci 10:95\u2013108.","journal-title":"Res Pharm Sci"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2017.06.003"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15041040"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.327"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-002-0488-8"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00170.x"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-16438-0_4"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01201-3"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200948030-00001"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.664465"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.03945.x"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-003-0636-9"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0243-9"},{"key":"e_1_3_2_41_2","unstructured":"World Health Organization. 2017. Guideline: alternative mass drug administration regimens to eliminate lymphatic filariasis. World Health Organization"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00562-26","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00562-26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:13:32Z","timestamp":1791472412000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00562-26"}},"subtitle":[],"editor":[{"given":"Vincent H.","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":40,"alternative-id":["10.1128\/aac.00562-26"],"URL":"https:\/\/doi.org\/10.1128\/aac.00562-26","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]},"assertion":[{"value":"2026-04-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00562-26"}}